Why it matters
The issue concerns patient data and trust in the UK’s National Health Service. Palantir is a U.S. company, but the article does not identify a direct effect on U.S. patients or services.
What happens next
The article describes Palantir’s request but does not report a decision to extend its tools to GP records. Any next steps or timetable are unclear.
Whether the UK government considers or approves use of Palantir’s tools with GP records
Any stated safeguards or response from the health minister or NHS